(Q46222219)

20 December 2017

title

Stability of an extemporaneous oral liquid aprepitant formulation (English)

1 reference

20 December 2017

author name string

L Lee Dupuis

series ordinal

1

1 reference

20 December 2017

Karen Lingertat-Walsh

series ordinal

2

1 reference

20 December 2017

Scott E Walker

series ordinal

3

1 reference

20 December 2017

publication date

29 November 2008

1 reference

20 December 2017

Supportive Care in Cancer

published in

1 reference

20 December 2017

volume

17

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

701-706

1 reference

20 December 2017

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-008-0539-5

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-008-0539-5

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

12 December 2020

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

12 December 2020

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

12 December 2020

Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant

1 reference

12 December 2020

Avoiding common flaws in stability and compatibility studies of injectable drugs

1 reference

12 December 2020

Stability studies: five years later

1 reference

12 December 2020

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

12 December 2020

Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.

1 reference

12 December 2020

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

12 December 2020

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

1 reference

12 December 2020

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)

1 reference

12 December 2020

10.1007/S00520-008-0539-5

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017